STAT+: How Trump’s latest pharma deals may undermine efforts to rein in drug costs

Analysts say private deals involve drugmakers agreeing to lower prices in Medicaid, where prices are low, in return for no price cuts in Medicare.

Original reporting by STAT · John Wilkerson. GridIndex is an aggregation and intelligence layer — full credit to the original publisher.